While a direct correlation exists between CD34+ cell dose and time to engraftment (120), ex vivo CD34+ selection of the leukoapheresis product is not only costly but has not been shown to improve outcomes in a recent retrospective analysis of autoimmune patients in the European Bone Marrow Transplantation (EBMT) database (119). This evidence concerns the gene CD34 and Autoimmunity.